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Abstract:
Propolis, an important honeybee product, have ethno pharmacological nutrients since
ancient times. It has a wide range of alleged applications including potential anti-
inflammatory and antioxidant effects. The aim of this study was the investigation of the
anti-inflammatory activity of Iranian propolis in type 2 diabetes mellitus (T2DM).
In the 8-week randomized double-blind controlled study, enrolled 60 patients with T2DM
were randomly assigned to propolis group (n = 30) and control group (n =30). Propolis
group received 500 mg three times a day for a total of 1500 mg/d of propolis pills, while
the control group received similar pills, lacking propolis. Interleukin 6 and Interleukin 17
were measured at the baseline and at the end of the study. Statistical analysis was
performed using SPSS software.
Eight weeks after drug administration, was a significant difference in mean IL-6 changes
(p=0.017) between the two groups, and IL-17 in propolis treated group significantly
decreased (p=0.02) in comparing with control group. Within groups analysis, the propolis
group showed remarkable changes in IL-6 (P<0.031) and IL-17 (P<0.015). There was no
significant reduction in IL-6 and IL-17 in the placebo group. The difference in the two
groups was significant.
Based on this study, the daily intake of 1500 mg of Iranian propolis supplement for 8
weeks led to decrease inflammatory factors IL-6 and IL-17 in patients with T2D.
